ThromboGenics’ JETREA® gains first Asian approval in Malaysia
ThromboGenics announces JETREA® (ocriplasmin) has been approved in Malaysia for treatment of adults with vitreomacular traction, including when associated with macular hole of diameter less than or equal to 400 microns. The approval was gained following a Priority Review granted in Sept. 2013. April 17, 2014